ÂÜÀòÂÒÂ×

Yueting Zheng is a highly experienced professional in the field of biomedicine, currently serving as Director of Process Development at Shinobi Therapeutics since January 2023. Prior to this role, Yueting held various leadership positions at Synthego Corporation, including Director of Cell and Gene Therapy and Associate Director of Preclinical, where responsibilities included leading a team focused on non-viral mediated gene integration in primary T cells and characterizing safety profiles of multiplex edited primary cells. Yueting's expertise extends to previous roles at Refuge Biotechnologies and the Center for Cell and Gene Therapy at Baylor College of Medicine, specializing in CAR-T and virus-specific T cell research. Academic qualifications include a Ph.D. in Virology and Immunology from Stony Brook University and a Master's in Virology from Wuhan University.